Status | Study |
Completed |
Study Name: The Effect of Bevacizumab on Corneal Neovascularization Condition: Corneal Neovascularization Date: 2008-11-22 Interventions: Drug: Bevacizumab subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 mon |
Completed |
Study Name: Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Condition: Corneal Neovascularization Date: 2008-10-07 Interventions: Drug: Ranibizumab 0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and |
Completed |
Study Name: Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) Condition: Corneal Neovascularization Date: 2008-05-19 Interventions: Drug: Ranibizumab 10 Patients will receive treatment (Ranibizumab) |
Completed |
Study Name: Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization Condition: Lipid Keratopathy Penetrating Keratoplasty Herpetic Kerato Date: 2008-05-19 Interventions: Drug: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg) subconjunctival injection of bevacizum |
Completed |
Study Name: Topical Avastin for Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2007-11-14 Interventions: Drug: Topical Avastin 1% Avastin (bevacizumab) 1% Ot |
Completed |
Study Name: Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Condition: Corneal Neovascularization Date: 2007-11-07 Interventions: Drug: Bevacizumab (Avastin) One dose of 0.1cc of subconjunctival Bevacizumab was applied |
Withdrawn |
Study Name: Corneal Thinning During Topical Bevacizumab Therapy Condition: Corneal Neovascularization Date: 2007-08-13 Interventions: Drug: bevacizumab (Avastin) |
Completed |
Study Name: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2007-08-06 Interventions: Drug: Bevacizumab (Avastin) Bevacizumab 10mg/mL 1 drop BID x 3 weeks |
Completed |
Study Name: Photodynamic Therapy With Verteporfin for Corneal Neovascularization Condition: Corneal Neovascularization Date: 2007-05-08 Interventions: Procedure: Photodynamic Therapy with Verteporfin |
Completed |
Study Name: Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization Condition: Corneal Neovascularization Date: 1999-10-18 Interventions: Drug: Dihematoporphyrin derivative Drug: p |